Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Deferred Taxes (2021 - 2025)

Historic Deferred Taxes for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to -$6.0 million.

  • Rxo's Deferred Taxes rose 1428.57% to -$6.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$21.0 million, marking a year-over-year decrease of 1052.63%. This contributed to the annual value of -$21.0 million for FY2025, which is 1052.63% down from last year.
  • As of Q4 2025, Rxo's Deferred Taxes stood at -$6.0 million, which was up 1428.57% from -$2.0 million recorded in Q3 2025.
  • In the past 5 years, Rxo's Deferred Taxes ranged from a high of $2.0 million in Q4 2021 and a low of -$12.0 million during Q4 2022
  • Over the past 5 years, Rxo's median Deferred Taxes value was -$4.5 million (recorded in 2023), while the average stood at -$4.6 million.
  • In the last 5 years, Rxo's Deferred Taxes crashed by 70000.0% in 2022 and then soared by 5714.29% in 2023.
  • Over the past 5 years, Rxo's Deferred Taxes (Quarter) stood at $2.0 million in 2021, then tumbled by 700.0% to -$12.0 million in 2022, then skyrocketed by 41.67% to -$7.0 million in 2023, then changed by 0.0% to -$7.0 million in 2024, then grew by 14.29% to -$6.0 million in 2025.
  • Its Deferred Taxes was -$6.0 million in Q4 2025, compared to -$2.0 million in Q3 2025 and -$2.0 million in Q2 2025.